Perlmutter Cancer Center

The purpose of the study is to determine the safety and tolerability of Glutaminase Inhibitor (BeGIN) CB-839 HCl in patients with NF1 mutant malignant peripheral nerve sheath tumors (MPNST), NF1 mutant cancers, KEAP1/NRF2 & STK11/LKB1 pathway aberrant tumors. CB-839 HCl is a potent and selective reversible inhibitor of glutaminase-1 activity. The study drug CB-839 HCl is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.